Case Study: How A Global Pharma Company Targeted a KOL Engagement Strategy Specific to Rheumatology
This case study is useful for anyone working to anticipate market access issues and develop plans for launching new drugs in key markets.
This case study is useful for anyone working to anticipate market access issues and develop plans for launching new drugs in key markets.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
In 2022, organizations gained ground in patient trust, decentralized clinical trials, virtual tools, and diverse conversations throughout the product development process. So – now what?
With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
2023 brings increased expectations from the FDA for patient-focused drug development (PFDD). Medical Affairs organizations need to develop new skills to put the patient voice at the center of drug, device, and diagnostic development and evaluation.
Congresses are often the best opportunity to connect with HCPs and KOLs. Learn 5 secrets for success.
Medical Affairs professionals across the globe became first-time Innovation Olympians, responded to a bold challenge, celebrated competition, accelerated innovation together, and shared a memorable experience together.
In this e-book, learn how medical affairs teams can use technology to address diversity issues in the drug development life cycle.
MAPS speaks with Eric Peacock, co-Founder and CEO of MyHealthTeam, about the alignment between social justice and business best-practices to promote health equity using patient communities.
